DNA X, Inc.

Listed Company

SONMCIK 0001178697NasdaqNon-AcceleratedSmaller ReportingTelephone & Telegraph ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-20.66M

Total Assets

—

Equity

—

Shares Out

1.49M

Op. Cash Flow

$-23.53M

SONM$3.36−70.72% · past yearDBEQ Basic

Daily closing prices

Business

DNA X, Inc. provides a cryptocurrency trading platform enabling users to buy, sell, and swap digital currencies against fiat and other cryptocurrencies. The platform features automated trading strategies, real-time settlement, and generates revenue through commissions on user trading activity. The company serves individual cryptocurrency traders globally via its dnax.us website and is developing additional products including staking and lending services.

Summary from 10-K filed 2026-04-15

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenues	—	—	94	70	55
Cost of revenues	—	—	74	58	48
Gross profit	—	—	19	12	6
General and administrative	5	3	8	11	10
Other	—	—	—	—	—
Total operating expenses	5	3	19	26	44
Net income (loss) from operations	−5	−3	513,000	−14	−38
Interest expense, net	−1	−29,000	−15,000	−97,000	—
Loss on extinguishment of debt	−161,000	—	—	—	—
Other income (expense), net	−902,000	246,000	−214,000	484,000	−459,000
Net loss from continuing operations before income taxes	−8	−3	284,000	−14	−38
Income tax expense from continuing operations	—	—	—	—	—
Net loss from continuing operations	−8	−3	—	—	—
Loss from discontinued operations, net of tax	−13	−31	—	—	—
Net loss	−21	−34	−90,000	−14	−39
Net loss per share basic, Continuing operations	−11	−11	—	—	—
Net loss per share diluted, Continuing operations	−11	−11	—	—	—
Net loss per share basic, Discontinued operations	−17.58	−117.37	—	—	—
Net loss per share diluted, Discontinued operations	−17.58	−117.37	—	—	—
Net loss per share basic, Net loss	−28.58	−128.37	−0.02	−0.49	−4.08
Net loss per share diluted, Net loss	−28.58	−128.37	−0.02	−0.49	—
Weighted-average shares used in computing net loss per share, basic	722,689	262,118	4	29	9
Weighted-average shares used in computing net loss per share, diluted	722,689	262,118	4	29	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	1	5	9	13	11
Prepaid expenses and other current assets	676,000	—	2	2	6
Current assets held for sale	27	27	—	—	—
Total Current assets	29	32	44	44	36
Investment in DNA X, LLC	1	—	—	—	—
Deferred tax assets	1	64,000	—	—	—
Other assets	274,000	384,000	3	3	3
Non-current assets held for sale	12	7	—	—	—
Total assets	44	40	56	54	41
Accounts payable	4	738,000	20	21	9
Accrued liabilities	704,000	250,000	12	11	11
Promissory notes, net	5	—	—	—	—
Derivative liability on convertible note	171,000	—	—	—	—
Current liabilities held for sale	38	43	—	—	—
Total current liabilities	48	44	32	32	21
Income tax payable	3	2	2	1	1
Total liabilities	51	45	34	34	22
Commitments and contingencies (Note 9)	—	—	—	—	—
Redeemable common stock, $0.001 par value; 223,201 shares issued and outstanding; redemption value $1,228 (Note 6)	1	—	—	—	—
Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,265,067 and 276,881 shares issued and outstanding at December 31, 2025 and 2024, respectively	1,000	—	4,000	41,000	19,000
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at December 31, 2025 and 2024	—	—	—	—	—
Additional paid-in capital	296	278	272	270	253
Accumulated deficit	−304	−284	−250	−250	−235
Total stockholders deficit	−8	−6	22	20	19
Total liabilities, redeemable common stock, and stockholders deficit	44	40	56	54	41

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	4	4	2	2	2
Stock-based compensation	2	2	1	2	1
Release of customer allowance liability	−6	—	—	—	—
Provision for credit losses	—	2	159,000	5,000	—
Inventory write-downs	—	887,000	—	—	2
Impairment of contract fulfillment assets	2	6	—	—	—
Other	358,000	110,000	97,000	−788,000	—
Accounts receivable	−1	7	−3	−12	−8
Non-trade receivable	−6	−6	1	−14,000	−2
Related party receivable	181,000	−181,000	—	—	—
Inventory	4	−5	−3	2	4
Prepaid expenses and other current assets	2	−3	426,000	4	2
Contract fulfillment assets	−11	−7	−5	−6	544,000
Other assets	−21,000	2	−43,000	−448,000	−3
Accounts payable	10	14	−1	12	617,000
Accrued liabilities	−2	8	1	−369,000	−83,000
Deferred tax assets	−1	−10,000	—	—	—
Income tax payable	899,000	171,000	99,000	20,000	166,000
Net cash used in operating activities	−24	−8	−4	−12	−38
Purchase of property and equipment	—	−214,000	−36,000	−8,000	−46,000
Net cash used in investing activities	—	−214,000	−36,000	−8,000	−46,000
Proceeds from issuance of common stock, net of issuance costs	14	4	—	14	28
Proceeds from promissory notes, net of issuance costs	6	—	—	—	—
Proceeds (payments) from short-term borrowings	−555,000	591,000	—	—	—
Proceeds from stock option exercises, net of taxes paid on vested restricted stock units	—	48,000	419,000	—	5,000
Net cash provided by financing activities	19	5	272,000	14	28
Net increase (decrease) in cash and cash equivalents	−4	−4	−4	2	−11
Cash paid for interest	945,000	29,000	15,000	97,000	—
Cash paid for income taxes	122,000	134,000	42,000	151,000	87,000
Purchase of DNA X LLC membership units for redeemable common stock	1	—	—	—	—
Accrued bonus settled in equity	1	—	—	—	—
Receivables transferred to satisfy payables	—	11	—	—	—
Bifurcation of the conversion feature in convertible note	171,000	—	—	—	—
Promissory note payments settled with equity	2	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is DNA X, Inc.'s CIK number?

DNA X, Inc.'s SEC CIK number is 0001178697 (1178697). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find DNA X, Inc.'s SEC filings?

All of DNA X, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did DNA X, Inc. last report earnings?

DNA X, Inc. (SONM) most recently filed an earnings 8-K with the SEC on May 20, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-024639). This is DNA X, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is DNA X, Inc.'s most recent earnings 8-K?

DNA X, Inc.'s latest earnings 8-K (Item 2.02) was filed May 20, 2026 under accession 0001493152-26-024639. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View DNA X, Inc.'s latest earnings 8-K →
Look up any company's CIK number →